{"protocolSection": {"identificationModule": {"nctId": "NCT01424813", "orgStudyIdInfo": {"id": "ABS-AS-301"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax\u00ae Versus a Placebo in People 12 Years and Older With Persistent Asthma", "officialTitle": "A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax\u00ae Versus Placebo in Subjects 12 Years and Older With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-08-25", "studyFirstSubmitQcDate": "2011-08-25", "studyFirstPostDateStruct": {"date": "2011-08-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-05-01", "resultsFirstSubmitQcDate": "2015-05-01", "resultsFirstPostDateStruct": {"date": "2015-05-20", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-05-08", "dispFirstSubmitQcDate": "2014-05-08", "dispFirstPostDateStruct": {"date": "2014-05-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-28", "lastUpdatePostDateStruct": {"date": "2015-06-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The study will measure the change in lung function in subjects with asthma after inhaling from either of two inhalers: Albuterol Spiromax\u00ae or placebo."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "dry powder inhaler", "short-acting beta2-agonist", "SABA", "bronchoconstriction", "bronchodilation", "bronchodilator", "metered dose inhaler"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 158, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo MDPI", "type": "PLACEBO_COMPARATOR", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.", "interventionNames": ["Drug: Placebo MDPI"]}, {"label": "Albuterol MDPI", "type": "EXPERIMENTAL", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.", "interventionNames": ["Drug: Albuterol MDPI"]}], "interventions": [{"type": "DRUG", "name": "Placebo MDPI", "description": "Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.", "armGroupLabels": ["Placebo MDPI"], "otherNames": ["Placebo Spiromax\u00ae"]}, {"type": "DRUG", "name": "Albuterol MDPI", "description": "Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.", "armGroupLabels": ["Albuterol MDPI"], "otherNames": ["ProAir\u00ae RespiClick, Albuterol Spiromax\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) of FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 1, Day 8 and Day 85"}], "secondaryOutcomes": [{"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 1.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 1"}, {"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 8.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 8"}, {"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 85.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "timeFrame": "Day 85"}, {"measure": "Participants With Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "timeFrame": "Day 1 to Day 92"}, {"measure": "Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group", "description": "Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint HEENT = head, eyes, ears, nose, throat", "timeFrame": "Day 1 (Baseline), Day 85"}, {"measure": "Participants With Clinically Significant Vital Sign Assessments", "description": "For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 \u00b1 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 \u00b1 5 and -5 minutes, then post-dose at 30 (\u00b15) minutes, 1hr (\u00b1 10 min), 2hr (\u00b1 10 min), 3hr (\u00b1 10 min), 4hr (\u00b1 10 min), 5hr (\u00b1 10 min) and 6 hr (\u00b1 10 min).\n\nSerial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:\n\nSystolic blood pressure: \\> 160 beats/minute Diastolic blood pressure: \\>100 beats/minute Heart rate: \\>120 beats/minute", "timeFrame": "Day 8, Day 85"}], "otherOutcomes": [{"measure": "Percent Change From Baseline in FEV1 AUC 0-6 Over the 12-week Treatment Period", "timeFrame": "Day 1, Day 8, Day 85"}, {"measure": "Percent Change From Baseline in FEV1 AUC 0-6", "timeFrame": "Day 1"}, {"measure": "Percent Change From Baseline in FEV1 AUC", "timeFrame": "Day 8"}, {"measure": "Percent Change From Baseline in FEV1 AUC", "timeFrame": "Day 85"}, {"measure": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose Over the 12-week Treatment Period", "timeFrame": "Day 1, Day 8, Day 85"}, {"measure": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 1", "timeFrame": "Day 1"}, {"measure": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 8", "timeFrame": "Day 8"}, {"measure": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 85", "timeFrame": "Day 85"}, {"measure": "Time to Onset of Effect (Change in FEV1 of 12% From Baseline Within 30 Minutes Postdose)", "timeFrame": "Day 1, Day 8, Day 85"}, {"measure": "Duration of Response Measured From the Time Post-dosing to the First Time After the Response Onset (Increase \u226512% Above Baseline) When the FEV1 Decreases to Less Than 12% Above Baseline (Within 6 Hours After Dosing) for Those Who Responded in 30 Minutes", "timeFrame": "Day 1, Day 8, Day 85"}, {"measure": "Time to Onset of Effect (Change in FEV1 of 15% From Baseline Within 30 Minutes Postdose)for Those Who Responded in 30 Minutes", "timeFrame": "Day 1, Day 8, Day 85"}, {"measure": "Duration of Response on Days 1, 8 and 85", "description": "Duration of response measured from the time post-dosing to the first time after the response onset (increase \u226515% above baseline) when the FEV1 decreases to less than 15% above baseline (within 6 hours after dosing) for those who responded within 30 minutes", "timeFrame": "Day 1, Day 8, Day 85"}, {"measure": "Percent of Symptom Free Days on the Patient Diary", "timeFrame": "Treatment days 1 through 85"}, {"measure": "Percent of Rescue Medication Free Days in the Patient Diary", "timeFrame": "Treatment days 1 through 85"}, {"measure": "Morning Peak Expiratory Flow Reading Reported on Patient Diary", "timeFrame": "Treatment days 1 through 85"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent/assent\n* General good health\n* Persistent asthma, with an FEV1 50-80% predicted.\n* Ability to perform spirometry in an acceptable manner as per protocol guidelines.\n* Ability to perform PEFR with a handheld peak flow meter.\n* Demonstration of reversible bronchoconstriction as verified by a 15% or greater increase from baseline FEV1.\n* Taking inhaled corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit.\n* Non-smokers.\n* Capable of understanding the requirements, risks, and benefits of study participation.\n* Other inclusion criteria apply.\n\nExclusion Criteria:\n\n* Participation in any investigational drug trial within the 30 days preceding the Screening Visit (SV).\n* A known hypersensitivity to albuterol or any of the excipients in the formulations.\n* History of severe milk protein allergy.\n* History of a respiratory infection or disorder that has not resolved within the 2 weeks preceding the Screening Visit (SV).\n* Currently requires treatment with \u03b22-adrenergic receptor antagonists or non-selective \u03b2-receptor blocking agents.\n* History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.\n* Any asthma exacerbation requiring oral corticosteroids within 3 months of the Screening Visit (SV). A subject must not have had any hospitalization for asthma within 6 months prior to the Screening Visit (SV).\n* Historical or current evidence of any clinically significant non-asthmatic acute or chronic condition including.\n* Other exclusion criteria apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Project Leader", "affiliation": "Teva Respiratory R&D", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 10077", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Teva Investigational Site 10079", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Teva Investigational Site 10569", "city": "Costa Mesa", "state": "California", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Teva Investigational Site 10053", "city": "Fountain Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Teva Investigational Site 10065", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Investigational Site 10572", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Investigational Site 10075", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Teva Investigational Site 10061", "city": "Roseville", "state": "California", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Teva Investigational Site 10066", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Teva Investigational Site 10068", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Teva Investigational Site 10069", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Teva Investigational Site 10058", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 10060", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 10064", "city": "Ormond Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.28581, "lon": -81.05589}}, {"facility": "Teva Investigational Site 10071", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Teva Investigational Site 10073", "city": "Wichita", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "Teva Investigational Site 10070", "city": "Owensboro", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Teva Investigational Site 10063", "city": "Bethesda", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "Teva Investigational Site 10571", "city": "Gaithersburg", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Teva Investigational Site 10067", "city": "Wheaton", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Teva Investigational Site 10072", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Teva Investigational Site 10050", "city": "Missoula", "state": "Montana", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Teva Investigational Site 10057", "city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Teva Investigational Site 10051", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Investigational Site 10078", "city": "Sylvania", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Teva Investigational Site 10054", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 10568", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 10055", "city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Teva Investigational Site 10056", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Investigational Site 10076", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Investigational Site 10684", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Teva Investigational Site 10570", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Teva Investigational Site 10049", "city": "Live Oak", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.56523, "lon": -98.3364}}, {"facility": "Teva Investigational Site 10052", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 10685", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Teva Investigational Site 10059", "city": "Fairfax", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Teva Investigational Site 10074", "city": "Puyallup", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.18538, "lon": -122.2929}}, {"facility": "Teva Investigational Site 10062", "city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}]}, "referencesModule": {"references": [{"pmid": "26369589", "type": "DERIVED", "citation": "Raphael G, Taveras H, Iverson H, O'Brien C, Miller D. Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. J Asthma. 2016;53(2):187-93. doi: 10.3109/02770903.2015.1070862. Epub 2015 Sep 15."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "384 patients screened; 180 patients were excluded on the basis of inclusion criteria, 4 due to exclusion criteria, 21 patients withdrew consent, 1 patient was lost to follow-up before the baseline visit, 6 patients had other reasons, and 14 patients failed to meet randomization criteria at the end of the run-in period.", "groups": [{"id": "FG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "FG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "79"}, {"groupId": "FG001", "numSubjects": "79"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "comment": "Safety set and full analysis set", "numSubjects": "79"}, {"groupId": "FG001", "comment": "Safety set and full analysis set", "numSubjects": "78"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "74"}, {"groupId": "FG001", "numSubjects": "77"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized participants", "groups": [{"id": "BG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "BG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "158"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.3", "spread": "16.84"}, {"groupId": "BG001", "value": "37.3", "spread": "16.89"}, {"groupId": "BG002", "value": "38.8", "spread": "16.88"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "12-17 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "30"}]}]}, {"title": "18-64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "63"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "123"}]}]}, {"title": "65+ years", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "91"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "67"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "114"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "39"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "149"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "82.4", "spread": "21.34"}, {"groupId": "BG001", "value": "83.4", "spread": "24.20"}, {"groupId": "BG002", "value": "82.9", "spread": "22.75"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "169.5", "spread": "9.47"}, {"groupId": "BG001", "value": "168.9", "spread": "9.27"}, {"groupId": "BG002", "value": "169.2", "spread": "9.35"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.6", "spread": "6.92"}, {"groupId": "BG001", "value": "29.2", "spread": "8.22"}, {"groupId": "BG002", "value": "28.9", "spread": "7.58"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) of FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set which includes all participants in the intent-to-treat (ITT) population who received at least 1 dose of study medication and had at least 1 post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L*hr", "timeFrame": "Day 1, Day 8 and Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.28", "spread": "0.091"}, {"groupId": "OG001", "value": "1.11", "spread": "0.092"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "mixed-model repeated-measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "1.08", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.128"}]}, {"type": "SECONDARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 1.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.52", "lowerLimit": "0.24", "upperLimit": "0.79"}, {"groupId": "OG001", "value": "1.58", "lowerLimit": "1.30", "upperLimit": "1.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "To adjust for multiplicity, so that the overall alpha level for all tests was controlled at the 0.05 level, tests were done sequentially \\[day 1, then day 8, then day 85\\] and terminated if individual results were not significant at the 0.05 level.", "statisticalMethod": "mixed model repeated measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.68", "ciUpperLimit": "1.46", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.198"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change From Baseline in FEV1 AUC 0-6 Over the 12-week Treatment Period", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1, Day 8, Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change From Baseline in FEV1 AUC 0-6", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change From Baseline in FEV1 AUC", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 8"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change From Baseline in FEV1 AUC", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose Over the 12-week Treatment Period", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1, Day 8, Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 1", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 8", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 8"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Maximum Percent Change From Baseline in FEV1 Within 2 Hours Post Dose on Day 85", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Time to Onset of Effect (Change in FEV1 of 12% From Baseline Within 30 Minutes Postdose)", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1, Day 8, Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Duration of Response Measured From the Time Post-dosing to the First Time After the Response Onset (Increase \u226512% Above Baseline) When the FEV1 Decreases to Less Than 12% Above Baseline (Within 6 Hours After Dosing) for Those Who Responded in 30 Minutes", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1, Day 8, Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Time to Onset of Effect (Change in FEV1 of 15% From Baseline Within 30 Minutes Postdose)for Those Who Responded in 30 Minutes", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1, Day 8, Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Duration of Response on Days 1, 8 and 85", "description": "Duration of response measured from the time post-dosing to the first time after the response onset (increase \u226515% above baseline) when the FEV1 decreases to less than 15% above baseline (within 6 hours after dosing) for those who responded within 30 minutes", "reportingStatus": "NOT_POSTED", "timeFrame": "Day 1, Day 8, Day 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent of Symptom Free Days on the Patient Diary", "reportingStatus": "NOT_POSTED", "timeFrame": "Treatment days 1 through 85"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent of Rescue Medication Free Days in the Patient Diary", "reportingStatus": "NOT_POSTED", "timeFrame": "Treatment days 1 through 85"}, {"type": "SECONDARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 8.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set of participants with data at the time point", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "Day 8", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.26", "lowerLimit": "0.03", "upperLimit": "0.49"}, {"groupId": "OG001", "value": "0.99", "lowerLimit": "0.76", "upperLimit": "1.22"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "To adjust for multiplicity, so that the overall alpha level for all tests was controlled at the 0.05 level, tests were done sequentially \\[day 1, then day 8, then day 85\\] and terminated if individual results were not significant at the 0.05 level.", "statisticalMethod": "mixed model repeated measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "1.06", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.164"}]}, {"type": "SECONDARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 85.\n\nFEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 \u00b1 5, and - 5 minutes, then post dose at 5 \u00b1 2, 15 \u00b1 5, 30 \u00b1 5, 45 \u00b1 5 minutes, and at 1hr \u00b1 5 min, 2hr \u00b1 5 min, 3hr \u00b1 5 min, 4hr \u00b1 5 min, 5hr \u00b1 5 min, and 6hr \u00b1 5 min.", "populationDescription": "Full analysis set of participants with data at the time point", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L*hr", "timeFrame": "Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "-0.15", "upperLimit": "0.28"}, {"groupId": "OG001", "value": "0.74", "lowerLimit": "0.53", "upperLimit": "0.96"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "To adjust for multiplicity, so that the overall alpha level for all tests was controlled at the 0.05 level, tests were done sequentially \\[day 1, then day 8, then day 85\\] and terminated if individual results were not significant at the 0.05 level.", "statisticalMethod": "mixed model repeated measures (MMRM)", "statisticalComment": "Fixed effects- pooled center, treatment group, study day, and study day by drug interaction, with baseline measured at each study day as covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.38", "ciUpperLimit": "0.99", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.154"}]}, {"type": "SECONDARY", "title": "Participants With Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 to Day 92", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "Any adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "Severe adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Other serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Withdrawn from study due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group", "description": "Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint HEENT = head, eyes, ears, nose, throat", "populationDescription": "Safety population. Only participants with both baseline and endpoint physical examination findings are summarized. Two placebo participants were missing endpoint physical examinations.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 (Baseline), Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "General appearance Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "76"}]}]}, {"title": "General appearance Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "General appearance Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "General appearance Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "HEENT Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "50"}]}]}, {"title": "HEENT Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "HEENT Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "HEENT Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Chest and Lungs Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "67"}]}]}, {"title": "Chest and Lungs Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Chest and Lungs Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Chest and Lungs Abnormal/abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Heart Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "77"}]}]}, {"title": "Heart Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Heart Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Heart Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Abdomen Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "77"}]}]}, {"title": "Abdomen Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Abdomen Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Abdomen Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Musculoskeletal Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}]}, {"title": "Musculoskeletal Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Musculoskeletal Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Musculoskeletal Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Skin Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "73"}]}]}, {"title": "Skin Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Skin Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Skin Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymph nodes Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "78"}]}]}, {"title": "Lymph nodes Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymph nodes Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymph nodes Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neurological Normal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "78"}]}]}, {"title": "Neurological Normal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neurological Abnormal/Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neurological Abnormal/Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Clinically Significant Vital Sign Assessments", "description": "For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 \u00b1 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 \u00b1 5 and -5 minutes, then post-dose at 30 (\u00b15) minutes, 1hr (\u00b1 10 min), 2hr (\u00b1 10 min), 3hr (\u00b1 10 min), 4hr (\u00b1 10 min), 5hr (\u00b1 10 min) and 6 hr (\u00b1 10 min).\n\nSerial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:\n\nSystolic blood pressure: \\> 160 beats/minute Diastolic blood pressure: \\>100 beats/minute Heart rate: \\>120 beats/minute", "populationDescription": "Safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 8, Day 85", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks."}, {"id": "OG001", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "Systolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Diastolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Heart rate - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Morning Peak Expiratory Flow Reading Reported on Patient Diary", "reportingStatus": "NOT_POSTED", "timeFrame": "Treatment days 1 through 85"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 to Day 92", "eventGroups": [{"id": "EG000", "title": "Albuterol MDPI", "description": "Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 78, "otherNumAffected": 6, "otherNumAtRisk": 78}, {"id": "EG001", "title": "Placebo MDPI", "description": "Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 79, "otherNumAffected": 9, "otherNumAtRisk": 79}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 79}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (16.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 78}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 79}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}